Form 8-K - Current report:
SEC Accession No. 0001193125-24-211066
Filing Date
2024-08-30
Accepted
2024-08-30 16:06:02
Documents
14
Period of Report
2024-08-27
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d838050d8k.htm   iXBRL 8-K 31896
2 EX-3.1 d838050dex31.htm EX-3.1 7954
  Complete submission text file 0001193125-24-211066.txt   170390

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20240827.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20240827_lab.xml EX-101.LAB 18740
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20240827_pre.xml EX-101.PRE 11714
16 EXTRACTED XBRL INSTANCE DOCUMENT d838050d8k_htm.xml XML 3836
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241269897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)